Nanotechnology Based Strategies for Cancer Immunotherapy (Record no. 66663)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06008nam a22006015i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-981-97-7022-9 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251030114940.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250207s2024 si | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789819770229 |
| -- | 978-981-97-7022-9 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-981-97-7022-9 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC261-271 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | R857.N34 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | thema |
| 245 10 - TITLE STATEMENT | |
| Title | Nanotechnology Based Strategies for Cancer Immunotherapy |
| Medium | [electronic resource] : |
| Remainder of title | Concepts, Design, and Clinical Applications / |
| Statement of responsibility, etc. | edited by Rajeev Sharma, Vikas Pandey, Neeraj Mishra. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. 2024. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Singapore : |
| Name of producer, publisher, distributor, manufacturer | Springer Nature Singapore : |
| -- | Imprint: Springer, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XVIII, 492 p. 43 illus., 42 illus. in color. |
| Other physical details | online resource. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS | |
| File type | text file |
| Encoding format | |
| Source | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Introduction to cancer immunotherapy -- Therapeutic hallmark of cancer & immunology -- Novel immunotherapeutic approaches for cancer therapy -- Recent advances in bio material for Immunotherapeutic applications -- Combination therapies for the management of cancer immunotherapy -- Cancer Vaccines as Immunotherapeutic frontier -- Dendritic Cell based approaches in cancer immunotherapy -- Peptides based Vaccines in cancer immunotherapy -- Monoclonal antibodies based nanobiotechnology based approaches in cancer immunotherapy -- Chimeric Antigen Receptor T Cells Based Cancer Immunotherapy -- Polymer and lipid based nanocomplexes in cancer immunotherapy -- Role of the tumor microenvironment in cancer immunotherapy -- Inorganic nanoparticles based strategies for Cancer Immunotherapy -- POLYMERIC NANOPARTICLES BASED STRATEGIES FOR CANCER IMMUNOTHERAPY -- Advances in Lipid-based nanosystem for immune induction in cancer immunotherapy -- Design, implementation and interpretation of clinical trials of cancer immunotherapy -- Ethical considerations of cancer immunotherapy, and patient perspectives on the benefits and risks of treatment -- REGULATORY ASPECTS OF CANCER IMMUNOTHERAPY -- Clinical applications, Patents and challenges in cancer immunotherapy. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This book will give an up-to-date and thorough exposition of the state of the art of concepts, design, and recent advances in nanobiotechnology-based strategies for cancer Immunotherapy, and their current and clinical status. Nanobiotechnology-based Targeted therapies and Immunotherapy have been added to the effective oncologic treatment and have become increasingly popular in oncology. It is intended to enable the researchers to prepare a variety of Nanobiotechnology-based strategies, investigate their properties, and discover their uses and applications in cancer immunotherapy. The novelty of the approach is to address an existing need to understand exhaustively the potential of the nanotechnology-based approaches, including targeted and smartly designed therapies, that deliver loaded immunoreactive (s) into the body at predefined sites. The book will also discuss the patents related to cancer immunotherapy. Because of the versatility and wide range of properties, nanobiotechnology-based systems are extensively used in cancer immunotherapy. The task of obtaining a versatile candidate in immune component(s) delivery seems to be intricated, as it has to surpass several vigorous clinical barriers. As a result, many scientists rely on nanobiotechnology-based approaches, which have already been approved and well-established. Over the years, extensive research has been undertaken on the delivery of immunoreactive(s) using nanotechnology-based delivery systems. With advancements in nanobiotechnology, more needs are realized to develop nanoengineered/smart delivery systems with even more convoluted properties. Currently, research is mainly focused on nanoengineered systems, which can perform one or more of the desired functions. The proposed book summarizes the basic principles and research supporting cancer immunotherapy clinical translation contains nanobiotechnology-based treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, treatment combinations Includes information on all FDA-approved immunotherapies, for individual cancer types, including melanoma and other skin cancers, lung cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain cancers, and breast cancer etc. Also explains the regulatory aspects behind the development and approval of immunotherapy drugs. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 4311 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 64703 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| General subdivision | Treatment. |
| 9 (RLIN) | 63722 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 69215 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| General subdivision | Immunological aspects. |
| 9 (RLIN) | 73413 |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 78154 |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 73414 |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 69215 |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | |
| 9 (RLIN) | 73415 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sharma, Rajeev. |
| Relator term | editor. |
| Relator code | edt |
| -- | http://id.loc.gov/vocabulary/relators/edt |
| 9 (RLIN) | 90707 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pandey, Vikas. |
| Relator term | editor. |
| Relator code | edt |
| -- | http://id.loc.gov/vocabulary/relators/edt |
| 9 (RLIN) | 90708 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mishra, Neeraj. |
| Relator term | editor. |
| Relator code | edt |
| -- | http://id.loc.gov/vocabulary/relators/edt |
| 9 (RLIN) | 74463 |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer Nature eBook |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Printed edition: |
| International Standard Book Number | 9789819770212 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Printed edition: |
| International Standard Book Number | 9789819770236 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Printed edition: |
| International Standard Book Number | 9789819770243 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1007/978-981-97-7022-9">https://doi.org/10.1007/978-981-97-7022-9</a> |
| 912 ## - | |
| -- | ZDB-2-SME |
| 912 ## - | |
| -- | ZDB-2-SXM |
No items available.